GlassScriptPhysician profile
Ali Marie Smith
NPI 1073097895
$2,032.33
in general payments reported to CMS, 2019-2025
32 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $160 · 2023: $688 · 2024: $722 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,871.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $304.53 | 2023-2025 | |
| Lilly USA, LLC | $245.33 | 2023-2025 | Mounjaro, Zepbound, Reyvow |
| Amgen INC. | $201.24 | 2022-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $169.44 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $156.36 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.34 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $95.22 | 2022-2025 | Rybelsus, Ozempic |
| Mylan Specialty L.P. | $80.72 | 2023-2024 | Yupelri |
| Astellas Pharma US INC | $71.12 | 2024 | Veozah |
| Daiichi Sankyo INC. | $56.55 | 2023-2024 | Injectafer |
| Grifols USA, LLC | $45.91 | 2023-2024 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $45.69 | 2024-2025 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $44.68 | 2023-2024 | Xarelto |
| Biohaven Pharmaceutical Holding Company LTD. | $29.62 | 2022 | |
| Glaxosmithkline, LLC. | $29.54 | 2023-2024 | Arexvy, Trelegy Ellipta |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $28.16 | 2024-2025 | Glassia |
| Merck Sharp & Dohme LLC | $27.89 | 2023-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Idorsia Pharmaceuticals US INC | $26.98 | 2023 | Quviviq |
| Organon LLC | $25.34 | 2023-2024 | Nexplanon |
| Corcept Therapeutics | $24.29 | 2023 | Korlym |
| Boston Scientific Corporation | $22.50 | 2024 | Watchman Flx |
| Sanofi Pasteur INC. | $19.18 | 2023 | |
| Medtronic, INC. | $18.15 | 2023 | Minimed 780g |
| Inspire Medical Systems, INC. | $17.35 | 2025 | Inspire |
| Abbott Laboratories | $17.15 | 2023 | Freestyle Libre 3 |
| Insmed, INC. | $16.63 | 2025 | Arikayce |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.31 | 2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $16.02 | 2023 | Austedo |
| E.R. Squibb & Sons, L.L.C. | $16.02 | 2024 | Eliquis |
| Phathom Pharmaceuticals, INC. | $14.54 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $14.01 | 2025 | |
| Genentech USA, INC. | $12.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.